Literature DB >> 8031516

Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989.

E J Beck1, J Kennelly, C McKevitt, L Whitaker, J Wadsworth, D L Miller, C Easmon, A J Pinching, J R Harris.   

Abstract

OBJECTIVE: To describe the use of hospital-based services and associated costs over time for HIV-infected individuals by disease stage and year of treatment.
METHODS: Data on service use were abstracted from inpatient and outpatient case-notes of 459 HIV-infected patients (121 asymptomatic and 338 AIDS patients) treated at St Mary's Hospital, London between 1983 and 1989. Cost estimates were derived from a survey of the 37 departments involved with HIV-related care. The number and type of admissions and outpatient visits, referral and discharge venues, number and type of tests and procedures performed, drugs prescribed and associated costs for the study period were the outcome measures used.
RESULTS: Most patients were homosexual men. At the time of first HIV-related visit, 80.7% lived in London. Most day cases and planned admissions were organized through the outpatient clinic; 31% of emergency admissions were initiated by patients themselves. For people with AIDS the number of day case admissions increased while planned admissions decreased. There was a marked reduction in the duration of inpatient stays, especially for AIDS patients. Costs associated with inpatient care decreased concomitantly. The number of outpatient visits for patients with symptomatic disease increased, resulting in increased outpatient expenditure. Asymptomatic patients had fewer inpatient tests, while outpatient tests did not change over time; costs followed similar patterns. Mean inpatient and outpatient drug-days prescribed did not change nor did average inpatient drug-costs although outpatient drug-costs increased. Inpatient tests performed on symptomatic non-AIDS patients decreased, while mean outpatient tests increased; average costs followed similar patterns. Inpatient drug-days prescribed and costs remained the same, while outpatient drug-days and average drug-costs increased during the study period. For AIDS patients, the number of inpatient tests performed and their average costs decreased but outpatient tests performed increased, though their average costs remained the same. Mean inpatient drug-days prescribed and average drug-costs decreased, while number of outpatient drug-days prescribed and average drug-costs increased markedly over time. For each disease category, expenditure on admissions and related tests decreased over time, while expenditure on outpatient visits and drug-costs increased.
CONCLUSIONS: The shift from an inpatient- to an outpatient-based service has resulted in fewer patients being investigated and treated in hospital and more as outpatients. This has resulted in a reduction of inpatient-related costs, while outpatient-related costs have increased. The overall contribution of drug-costs to the total cost has increased greatly over time. With the anticipated advent of new antiviral compounds, the importance of ascertaining their effectiveness as well as their efficacy will become crucial.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031516     DOI: 10.1097/00002030-199403000-00012

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

Review 1.  Health economics in HIV disease. A review of the European literature.

Authors:  M Youle; P Trueman; K Simpson
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 2.  Current controversies in the treatment of HIV infection and AIDS. An economic perspective.

Authors:  S Petrou
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

3.  Hospital care for persons with AIDS in European-Union countries; a cross-country comparison.

Authors:  M J Postma; H Kornarou; V Paparizos; R M Leidl; K Tolley; J Kyriopoulos; J C Jager
Journal:  Health Care Manag Sci       Date:  2000-01

4.  Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.

Authors:  E J Beck; S Mandalia; R Griffith; J Beecham; M D Walters; M Boulton; D L Miller
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

5.  Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.

Authors:  J V Chancellor; A M Hill; C A Sabin; K N Simpson; M Youle
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

6.  The economic costs of caring for people with HIV infection and AIDS in England and Wales.

Authors:  S Petrou; M Dooley; L Whitaker; E Beck; E Kupek; J Wadsworth; D Miller; A Renton
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 7.  The cost of HIV treatment and care. A global review.

Authors:  E J Beck; A H Miners; K Tolley
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

8.  The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs.

Authors:  E J Beck; K Tolley; A Power; S Mandalia; P Rutter; J Izumi; J Beecham; A Gray; D Barlow; P Easterbrook; M Fisher; J Innes; G Kinghorn; B Mandel; A Pozniak; A Tang; D Tomlinson; I Williams
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

9.  Hospital utilization and costs in a cohort of injection drug users.

Authors:  A Palepu; M W Tyndall; H Leon; J Muller; M V O'Shaughnessy; M T Schechter; A H Anis
Journal:  CMAJ       Date:  2001-08-21       Impact factor: 8.262

10.  A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy.

Authors:  Andrea Tramarin; Stefano Campostrini; Maarten J Postma; Guido Calleri; Keith Tolley; Nicoletta Parise; Fausto de Lalla
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.